Halobetasol Propionate/Tazarotene

丙酸乌倍他索/他扎罗汀

Report date: 2025/11/27 15:37:23

Base Information

Drug NameHalobetasol Propionate/Tazarotene
Drug Alias NameHalobetasol Propionate-Tazarotene mixt他扎罗汀/丙酸乌倍他索丙酸乌倍他索和他扎罗汀Halobetasol Propionate and Tazarotene乌倍他索/他扎罗汀 +[16] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionRetinoic acid receptor gamma agonistsCytosolic phospholipase A2 agonistsRetinoic acid receptor beta agonists +[5] 
TargetsGlucocorticoid receptorCytosolic phospholipase A2Retinoic acid receptor beta +[5] 
Therapy Area/IndicationsPlaque psoriasisPsoriasis
Global Approved IndicationsPsoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/04/25
Country/TerritoryUnited States
CombinationsYes TazaroteneHalobetasol Propionate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesValeant
China Registration ClassN/A

Develop Information

Active CompaniesBausch & Lomb (Singapore) Pvi LtdAustin Institute for Clinical Research
Inactive CompaniesBausch Health Americas IncDow Pharmaceutical Sciences Inc
Active IndicationsPlaque psoriasisPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeD05
Related LinksN/A